3-Mercapto-1H-indazol | 27006-38-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 3-Mercapto-1H-indazol
• 英文别名: 1H-indazole-3-thiol；1H-Indazole-3-thiol；1,2-dihydroindazole-3-thione
• CAS: 27006-38-8
• 化学式: C₇H₆N₂S
• 分子量: 150.204
• InChiKey: QZQLBBPKPGSZBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56.2
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
  申请人：Wyeth

  公开号：US20040167122A1

  公开（公告）日：2004-08-26

  The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor. 1

  本发明提供了一种I式化合物及其在治疗与5-HT6受体相关或受其影响的疾病中的应用。
• Neuronal Pain Pathway Modulators
  申请人：Ambron Richard

  公开号：US20080176920A1

  公开（公告）日：2008-07-24

  The present invention relates to compounds that may be used to inhibit activation of protein kinase G (“PKG”). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the active site of PKG and/or are analogs of balanol.

  本发明涉及可用于抑制蛋白激酶G（PKG）激活的化合物。至少部分基于对PKG的三级结构的发现以及发现绑定于PKG活性位点和/或是巴洛酮类似物的分子的识别。
• [EN] COMPOUNDS CONTAINING A SULFONIC GROUP AS KAT INHIBITORS<br/>[FR] COMPOSÉS CONTENANT UN GROUPE SULFONIQUE EN TANT QU'INHIBITEURS DE KAT
  申请人：EPIZYME INC

  公开号：WO2018102419A1

  公开（公告）日：2018-06-07

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供了化合物、其药用可接受的组合物以及使用相同的方法。
• [EN] INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF<br/>[FR] INHIBITEURS DE KINASE 12 DÉPENDANTE DES CYCLINES (CDK12) ET LEURS UTILISATIONS
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2018098361A1

  公开（公告）日：2018-05-31

  The present invention provides novel compounds of Formulae (I') and (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, ovarian cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., CDK12), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

  本发明提供了式(I')和(II)的新化合物，以及这些化合物的药学可接受的盐、溶剂合物、水合物、多晶形态、共晶体、互变异构体、立体异构体、同位素标记衍生物、前药和其组合物。还提供了涉及这些新颖化合物或组合物的方法和试剂盒，用于治疗和/或预防增生性疾病（例如，癌症（例如，白血病、急性淋巴细胞白血病、淋巴瘤、伯基特淋巴瘤、黑色素瘤、多发性骨髓瘤、乳腺癌、尤因氏肉瘤、骨肉瘤、脑癌、卵巢癌、神经母细胞瘤、肺癌、结肠直肠癌）、良性肿瘤、与血管生成有关的疾病、炎症性疾病、自身炎症性疾病和自身免疫疾病）的主体。使用本发明的化合物或组合物治疗患有增生性疾病的主体可能抑制激酶（例如，细胞周期依赖性激酶（CDK）（例如，CDK12））的异常活性，从而诱导主体内的细胞凋亡和/或抑制转录。
• AMINOAZACYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
  申请人：Haydar Simon Nicolas

  公开号：US20080293688A1

  公开（公告）日：2008-11-27

  The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.

  本发明提供了一种式I的化合物及其在治疗与5-HT6受体相关或受其影响的疾病中的应用。